Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients

被引：4
|
作者：
Funk, R. K. [1 ]
Davis, B. J. [1 ]
Mynderse, L. A. [1 ]
Wilson, T. M. [1 ]
Deufel, C. L. [1 ]
Furutani, K. M. [1 ]
Pisansky, T. M. [1 ]
Haddock, M. G. [1 ]
Choo, C. R. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2535
引用
收藏
页码：E213 / E214
页数：2
相关论文
共 50 条
  • [31] Permanent prostate brachytherapy for intermediate risk prostate cancer
    Frazier, AJ
    Keole, SR
    Forman, JD
    Cher, M
    Zuniga, C
    Rosemberg, S
    RADIOLOGY, 2002, 225 : 266 - 267
  • [32] HDR brachytherapy as monotherapy for low and intermediate risk prostate cancer
    Gaudet, M.
    Pharand-Charbonneau, M.
    Wright, D.
    Desrosiers, M.
    Haddad, A.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S1188 - S1188
  • [33] Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy
    Kwok, Y
    DiBiase, SJ
    Amin, PP
    Naslund, M
    Sklar, G
    Jacobs, SC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (03): : 588 - 594
  • [34] Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer
    Muralidhar, Vinayak
    Mahal, Brandon A.
    Ziehr, David R.
    Chen, Yu-Wei
    Nezolosky, Michelle D.
    Viswanathan, Vidya B.
    Beard, Clair J.
    Devlin, Phillip M.
    Martin, Neil E.
    Orio, Peter F., III
    Nguyen, Paul L.
    BRACHYTHERAPY, 2015, 14 (04) : 511 - 516
  • [35] Outcome of young patients treated with 125I-brachytherapy for low and intermediate risk prostate carcinoma
    Kindts, I.
    Stellamans, K.
    Pottel, H.
    Lambrecht, A.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S156 - S156
  • [36] New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage
    Brun, Thomas
    Bachaud, Jean-Marc
    Graff-Cailleaud, Pierre
    Malavaud, Bernard
    Portalez, Daniel
    Popotte, Christian
    Aziza, Richard
    Lusque, Amelie
    Filleron, Thomas
    Ken, Soleakhena
    BRACHYTHERAPY, 2018, 17 (03) : 544 - 555
  • [37] Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy
    Ghadjar, Pirus
    Keller, Tamara
    Rentsch, Cyrill A.
    Isaak, Bernhard
    Behrensmeier, Frank
    Stroux, Andrea
    Thalmann, George N.
    Aebersold, Daniel M.
    BRACHYTHERAPY, 2009, 8 (01) : 45 - 51
  • [38] Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity, seeds for I-125 permanent seed prostate brachytherapy
    Delouya, Guila
    Bahary, Pascal
    Carrier, Jean-Francois
    Larouche, Renee-Xaviere
    Hervieux, Yannick
    Beliveau-Nadeau, Dominic
    Donath, David
    Taussky, Daniel
    BRACHYTHERAPY, 2015, 14 (03) : 329 - 333
  • [39] Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    King, Christopher R.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (03) : 268 - 278
  • [40] LONG TERM BIOCHEMICAL AND SURVIVAL OUTCOME OF 921 PATIENTS TREATED BY I-125 PERMANENT PROSTATE BRACHYTHERAPY
    Battermann, J. J.
    Hinnen, K.
    Moerland, M.
    van Vulpen, M.
    RADIOTHERAPY AND ONCOLOGY, 2009, 91 : S11 - S11
12345